Sep 17, 2019 7:00 am EDT Capricor Therapeutics to Present Results from the HOPE-2 Trial of CAP-1002 in Duchenne Muscular Dystrophy in a Late Breaking Session of the World Muscle Society
Aug 06, 2019 4:00 pm EDT Capricor Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Jul 30, 2019 8:00 am EDT Capricor Therapeutics to Present Second Quarter 2019 Financial Results and Recent Corporate Update on August 6
Jul 25, 2019 7:00 am EDT Capricor Therapeutics Announces Positive DSMB Safety and Futility Review and Continuation of its HOPE-2 Study in Duchenne Muscular Dystrophy
Jul 17, 2019 7:00 am EDT Capricor Therapeutics and Parents Project Muscular Dystrophy to Host Webinar to Discuss Interim Analysis of the HOPE-2 Clinical Trial to Treat Patients with Duchenne Muscular Dystrophy
Jul 15, 2019 6:00 am EDT Capricor Therapeutics Announces Positive Results from its Interim Analysis in the HOPE-2 Trial to Treat Patients with Duchenne Muscular Dystrophy
May 13, 2019 4:00 pm EDT Capricor Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
May 06, 2019 4:00 pm EDT Capricor Therapeutics to Present First Quarter 2019 Financial Results and Recent Corporate Update on May 13
Mar 28, 2019 4:00 pm EDT Capricor Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update